ResearchMoz

Pharmaceuticals Monthly Deals Analysis: October 2013 - Partnerships, Licensing, Investments and M&A Trends

GlobalData
Published Date » 2013-11-30
No. Of Pages » 107
   
 GlobalData's Pharmaceuticals Monthly Deals Analysis: October 2013 Partnerships, Licensing, Investments and M&A Trends report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals...
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2013 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
2.2.1 McKesson to Acquire Celesio for US$8.3 Billion 14
2.2.2 Bristol-Myers Squibb Completes Public Offering of Notes for US$1.5 Billion 16
2.2.3 Ventas Acquires Portfolio of Independent Living Communities from Holiday Retirement for US$790 Million 16
2.2.4 BioMarin Pharma Completes Public Offering of Notes for US$750 Million 16
2.2.5 Astellas Pharma Enters Into R&D Agreement with Mitokyne for Drug Discovery 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2013 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2013 19

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2013 20
3.1.1 Top M&A Deals in October 2013 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2013 - October 2013 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2013 23
3.2.1 Top Equity Offering Deals in October 2013 24
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2013 - October 2013 25
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2013 27
3.3.1 Top PE/VC Deals in October 2013 28
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2013 29
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2013 31
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, May 2013-October 2013 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013-October 2013 34

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2013 - October 2013 37
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 39
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2013 41
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2013 - October 2013 44
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 45
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 51
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2013 53
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2013 53
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2013 54
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2013 - October 2013 55
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 57
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2013 - October 2013 59
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 61

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 63
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2013 63
6.1.1 Oncology - Deals of the Month 65
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2013 67
6.2.1 Central Nervous System - Deals of the Month 69
6.3 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2013 70
6.3.1 Immunology - Dealsof the Month 72
6.4 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2013 73
6.4.1 Infectious Diseases - Deals of the Month 75
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, October 2013 76
6.5.1 Metabolic Disorders - Deal of the Month 78
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2013 81
6.6.1 Cardiovascular - Deal of the Month 82
6.7 Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals, October 2013 84
6.7.1 Hematological Disorders - Deal of the Month 85

7 Deal Summary by Geography 87
7.1 Pharmaceuticals & Healthcare, North America Deals, October 2013 87
7.1.1 North America - Deals of the Month 89
7.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2013 91
7.2.1 Europe - Deals of the Month 92
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2013 94
7.3.1 Asia-Pacific - Deals of the Month 96
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2013 97
7.4.1 Rest of the World - Deals of the Month 99

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 100
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2013 - October 2013 100
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2013 - October 2013 102

9 Further Information 104
9.1 Methodology 104
9.2 About GlobalData 105
9.3 Disclosure information 106
9.4 Disclaimer 106

List of Tables


Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2013 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2013 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2013 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 26
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 28
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2013 28
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2013 - October 2013 30
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2013 32
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013 - October 2013 34
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 36
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 38
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 40
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 41
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 43
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 46
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2013 - October 2013 48
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 50
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 52
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2013 53
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2013 53
Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2013 54
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 56
Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2013 58
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 60
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 62
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 64
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 68
Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 71
Table 35: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 74
Table 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 77
Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 82
Table 38: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 85
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 88
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 92
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 95
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 98
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 101
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 103

List of Figures


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2013 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2013 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 20
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 23
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 25
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 27
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 29
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2013 31
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2013 32
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 35
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 37
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 39
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 44
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 45
Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47
Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 49
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 51
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 55
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 57
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2013 - October 2013 59
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 60
Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 61
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 63
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 67
Figure 29: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 70
Figure 30: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 73
Figure 31: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 76
Figure 32: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 81
Figure 33: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 84
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 87
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 91
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 94
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 97
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 100
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 102

Upcoming Reports:

Fiberglass Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Fiberglass, which is also known as glass reinforced plastics, is manufactured by reinforcing the plastic matrix using fine fibers of glass. Fiberglass being light weight, robust material and extremely strong are used extensively for manufacturing a wide range of products. The raw material required to manufacture fiber glass is easily available at low cost, thus, making it favorable than carbon fibers for various applications. Moreover, fiberglass being less brittle, has good bulk strength and weight properties which helps it to easily replace metals used in manufacturing several products...
Energy Conservation And Efficiency Market - Global Industry Analysis, Size, Share, Trends, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
Energy conservation is reduction in amount of energy consumed, whereas energy efficiency is using less energy for any constant service. Both are energy reduction techniques. Energy conservation results in increased environmental quality, personal financing security and national security. The Energy efficiency markets distributes goods and services which reduces energy used to fuel our economies.  The concern regarding carbon emissions and increase in consumption of power has demanded for energy efficient systems. Manufacturing industries are one of the major consumers of...
Cancer/Tumor Profiling Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Cancer is a fatal disease characterized by uncontrolled cell division. It is primarily caused by environmental factors that mutate the gene encoding for cell regulation. The resultant cell aberration leads to abnormal cell growth that destroys the surrounding normal tissue and thus spreads the disease to vital organs. Cancer diagnosis is performed in a number of ways that include screening tests and medical imaging. According to WHO, cancer is one of the leading cause of death and is estimated to account for 11.5 million deaths in 2030 worldwide. Cancer diagnosis is performed in a...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

British Stocks Fell Flat after Decline in Retail Sales
Apr 23, 2015  
The shares of the top British companies were left mostly unchanged on Thursday, April 23, 2015, after an unforeseen fall in the national retail sales for this month making up for an increase in the utilities shares just 2 weeks before the general election. Whereas the expectation for a single party to win an outright majority on May 7, 2015 is very low, and the experts forecasting a...
Retail Clinics Touched 10 Million Annual Visits
Apr 23, 2015  
The proliferation of retail health means Americans are visiting retail clinics more than 10 million times a year at 1,800-plus locations, yet this convenient and low cost care model accounts for just a fraction of primary care in the U.S. Manatt Health, a health care consulting firm, said retail clinics represent about 2% of “all primary care encounters” in the U.S. even with the...
China Imposes a Fine on Mercedes of US$57 million
Apr 23, 2015  
A Chinese regulator said Thursday it has fined Mercedes Benz US$57 million on price-fixing charges in a wide-ranging probe of the auto industry that has prompted complaints foreign automakers are being treated unfairly. The unit of Germany's Daimler AG was fined for violating anti-monopoly law by enforcing minimum prices dealers were required to charge for vehicles and replacement parts,...
Zinc to Surpass Gold for Personal Portfolios
Apr 23, 2015  
The precious metals such as gold are in low gear, although miners are trying to have a better look. A lot of the Oxford Club Members are trying to give a fill to their metal portfolios.  There is speculation about zinc to outperform this year. Since mid March, the metal is up by 12.9% already. The numbers are much better than gold and market estimates are it is going to go even...
Copper Traders in the World Bracing for Inventory
Apr 23, 2015  
The copper traders in the world are in a dreaded state. China which is large consumer of copper has withdrawn demand due to slowdown of building boom, and market data for the week elucidates higher volumes consumed for intermediate copper concentrates rather than the finished material which has been the mainstay of global trade. It is sign of further tough times for copper traders, as...